Neutropenia Clinical Trial
Official title:
Neutrocheck Summative Usability Study
This study proposes to assess the usability of the Neutrocheck device and test kit amongst healthy volunteers and healthcare professionals (HCPs). Neutrocheck is a portable, single-use diagnostic test intended to aid the diagnosis of neutropenia, febrile neutropenia and neutropenic sepsis using a finger prick blood sample. Neutropenia is when the number of infection-fighting neutrophil cells in the blood are lower than normal. It can be caused by treatments such as chemotherapy or by certain medical conditions. Neutropenic sepsis is a life-threatening medical emergency that occurs when patients with neutropenia develop an infection. There is currently no way to test for neutropenic sepsis outside of hospitals. Neutrocheck is being developed for use as a self-test by patients at home alongside remote consultation with a HCP or at point-of-care by a HCP. This will allow rapid identification of patients requiring urgent intravenous antibiotics and medical assessment. In cases where Neutrocheck has eliminated the possibility of neutropenic sepsis, patients can avoid unnecessary and stressful hospital visits and valuable hospital resources will be saved. Participants in this study will be invited to use the Neutrocheck test kit in a setting similar to a home environment to carry out a test, whilst being observed by a study moderator. The Neutrocheck devices used in the study will be for investigational use only. This study will not be testing the accuracy of the Neutrocheck result, rather if Neutrocheck can be used safely and in a user-friendly way. Results will not be considered valid. Planned study duration is 2 months. This approach will enable us to complete the current phase of development and advance to a clinical validation study of Neutrocheck, assessing the diagnostic accuracy of Neutrocheck amongst users including those at risk of neutropenia and neutropenic sepsis.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02452034 -
Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)
|
Phase 1 | |
| Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A | |
| Not yet recruiting |
NCT01714557 -
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT00020865 -
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
|
Phase 3 | |
| Completed |
NCT00257790 -
The Tobramycin Study
|
Phase 4 | |
| Completed |
NCT00020371 -
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
|
Phase 1 | |
| Terminated |
NCT00005787 -
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Completed |
NCT00001533 -
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
|
Phase 1 | |
| Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
| Not yet recruiting |
NCT02238873 -
Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma
|
Phase 3 | |
| Completed |
NCT01058993 -
AMD 3100 for Treatment of Myelokathexis
|
Phase 1 | |
| Completed |
NCT00771810 -
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
|
Phase 2 | |
| Completed |
NCT00770172 -
G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
|
Phase 3 | |
| Terminated |
NCT00529282 -
A Study of Ceftobiprole in Patients With Fever and Neutropenia.
|
Phase 3 | |
| Completed |
NCT00771433 -
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT00030758 -
Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
|
Phase 4 | |
| Completed |
NCT00001790 -
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
|
Phase 1 | |
| Completed |
NCT00002693 -
Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia
|
Phase 1 | |
| Active, not recruiting |
NCT04154488 -
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
|
Phase 1/Phase 2 |